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Abstract
Background: A tumor necrosis factor-alpha is a multifunctional pro-inflammation cytokine, which has been
considered as one of pathogenic factors for various diseases. The promoter -1031(T/C) polymorphism in the tumor
necrosis factor-alpha gene was reported that it plays a part in reproduction-related diseases. Among these,
polycystic ovary syndrome (PCOS) is known to be a common gynecological disease of women in reproductive age
women. Here, we performed a comparative study of -1031(T/C) polymorphism of TNF-alpha gene with PCOS in a
Korean population.
Methods: The -1031(T/C) polymorphism of TNF-alpha gene was analyzed by polymerase chain reaction restriction
fragment length polymorphism (PCR-RFLP) in a total of 217 PCOS patients and 144 matched female controls of
healthy women. And statistical analysis was performed using HapAnalyzer. X
2 test and logistic regression were
utilized analyze the association between two groups. A p-value under 0.05 was considered statistically significant.
Results: The genotype and allelic frequencies were in Hardy-Weinberg equilibrium (HWE). There was strong
association between the -1031(T/C) polymorphism in the promoter region of TNF-alpha gene and PCOS (p-value =
0.0003, odd ratio (OR) = 2.53). In addition, the frequency of C allele was significantly higher in PCOS patients
compared with controls. Sequence analyses also showed the -1031(T/C) polymorphism of TNF-alpha gene.
Conclusion: This is the first study on the -1031(T/C) polymorphism of TNF-alpha gene in PCOS. We concluded that
the -1031(T/C) polymorphism of TNF-alpha gene is associated with PCOS in a Korean population. Therefore, it is
possible that it may be considered as a clinical biomarker to diagnose for PCOS, and is helpful in understanding
the etiology for the pathogenesis of PCOS.
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Background
Polycystic ovary syndrome (PCOS) is one the most com-
mon gynecological disorder and affects up to 5% women
in reproductive ages [1-4]. Generally, PCOS patients show
the symptoms of obesity, increased risk of type 2 diabetes
mellitus, menstrual irregularity, and anovulation [5-9]. A
number of groups focused on the studies for single
nucleotide polymorphisms and expected that could be
associated with PCOS. However, its etiology is still not
fully identified [10,11].
Up to now, several association studies were reported
that the some of polymorphisms of tumor necrosis
factor-a (TNF-a) are related with gynecological diseases
including pre-eclampsia, endometriosis [12]. It is a mul-
tifunctional proinflammation cytokine and has a signifi-
cant source of genetic variability [13,14]. Many studies
suggested that the TNF-a may be considered as an
immunological and molecular indicator for gynecologi-
cal-related diseases. A previous study showed that -857
(C/T) and -863(C/A) polymorphisms in TNF-a gene
showed no effect on endometriosis patients in a Japa-
nese population [15]. Additional genetic studies of -238
(G/A) and -308(G/A) promoter polymorphisms in a
TNF-a gene have no association with endometriosis in a
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polymorphism does not affect genetic susceptibility to
polycystic ovaries [17]. In contrast, only -1031(T/C)
polymorphism in a TNF-a gene plays a part of endome-
triosis in Asian populations [15,18]. Even though there
are no extensive genetic studies performed on PCOS,
previous studies suggest that the -1031(T/C) poly-
morphism in a TNF-a gene may affect PCOS. Here, we
investigated the relationship between SNP in -1031(T/C)
of TNF-a gene and PCOS to investigated -1031(T/C)
polymorphism in a TNF-a gene is associated with
PCOS.
Methods
Subjects
All samples were recruited from at Fertility Center of
CHA General Hospital in Seoul, Korea. The study
appraised 217 PCOS patients and 144 healthy Korean
women as case and control groups based on the revised
diagnostic criteria according to the 2003 ASRM/ESHRE
Rotterdam consensus.
Written informed consent was obtained from all of
the participating women. Blood samples were collected
in tubes containing EDTA as an anti-clotting factor
and stored at -20°C until use. Genomic DNA was iso-
lated from the blood samples of PCOS patients and
controls. PCOS patients and controls in this study
were all Korean women and this study with human
blood samples was authorized by an Institutional
Review Board (IRB).
Biochemical determinations
The clinical and biochemical characteristics of the PCOS
patients and controls are indicated in Table 1. Blood
samples were collected from both PCOS patients and
controls. Hormone and glucose levels, including plasma
L H ,F S H ,P R L ,E 2, TSH, testosterone, and DHEA-S were
measured as indicators of distinction.
Genetic analysis
To investigate the association between the -1031(T/C)
polymorphism of TNF-a gene and PCOS, we collected
217 PCOS patients sample and 144 control samples, and
polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) analysis was performed. The
-1031(T/C) polymorphism of TNF-a gene was amplified
by PCR with a set of primers, 5’-TAT GTG ATG GAC
TCA CCA GG-3’ and 5’-CCT CTA CAT GGC CCT GTC
TT-3’. The 30 cycles of PCR was perform at 96°C for
5 min, 94°C for 30 sec, 63°C for 40 sec, and 72°C for
1 min and final cycle of 72°C for 10 min. Amplified PCR
products were purified using AccuPrep Bioneer’sP C R
purification kit (Bioneer, Daejeon, Korea), and digested
with Bbs I (New England BioLabs, Beverly, MA, USA) for
14 hrs at 37°C.
DNA fragments were electrophoresed on 2% agarose gels
containing ethidium bromidei n0 . 5 ×T r i s - B o r a t e - E D T A
buffer. Stained fragments were visualized under ultraviolet
transilluminator. The fragments of 251- and 13-bp revealed
homozygosity for the T allele and 180-, 71- and 13-bp frag-
ments indicated homozygosity for the C allele (Figure 1). In
addition, PCR products of each genotype were sequenced
to confirm the genotyping results from the RFLP analysis.
Statistical analysis
Statistical analysis was performed using HapAnalyzer. X
2
test and logistic regression were utilized to analyze the
association between two groups. A p-value under 0.05
was considered statistically significant.
Results
According to the instruction of the ASRM/ESHRE Rot-
terdam consensus in 2003, PCOS patients showed fol-
lowing two of the three phenotypes: clinical or
biochemical hyperandrogenism, oligo- or amenorrhea
and polycystic ovarian morphology through ultrasono-
graphy. To validate the clinical and biochemical
Table 1 Clinical and biochemical characteristic of PCOS patients (n = 217) and normal controls (n = 144)
Characteristics PCOS patients (n = 217) Controls (n = 144)
Age (y) 32.47 ± 3.04 (29-35) 33.09 ± 3.36 (29-36)
BMI (kg/m2) 34.99 ± 5.84 (24.38-56.23) 18.77 ± 2.13 (15.04-25.08)
Waist/hip ratio (WHR) 1.23 ± 0.09 (1.00-2.24) 0.72 ± 0.06 (0.63-0.82)
FSH (mIU/ml) 8.75 ± 2.75 (1.50-29.98) 5.93 ± 1.64 (2.71-12.22)
LH (mIU/ml) 12.61 ± 9.87 (1.50-37.67) 2.93 ± 1.34 (1.01-6.43)
E2 (pg/ml) 64.69 ± 52.11 (7.53-133.36) 29.4 ± 13.7 (3.84-58.05)
Prolactin (ng/ml) 20.22 ± 14.52 (3.46-108.80) 11.08 ± 5.86 (3.71-42.02)
TSH (μIU/ml) 3.39 ± 2.15 (0.69-15.74) 1.7 ± 0.85 (0.02-3.67)
DHEA-S (μg/dl) 298.48 ± 115.34
(68.26-568.41)
142.96 ± 50.22
(60.86-233.11)
Testosterone (ng/ml) 0.87 ± 0.31 (0.09-1.29) 0.22 ± 0.13 (0.01-0.48)
Numerical data were presented as means ± standard deviation (SD). Abbreviations: BMI, Body mass index: WHR, Waist-hip ratio: FSH, Follicle-stimulating
hormone: LH, Luteinizing hormone: E2, Estradiol: TSH, Thyroid-stimulating hormone; DHEA-S, Dehydroepiandrosterone-sulfate
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subjects were measured for body mass index (BMI),
waist/hip ratio (WHR), glucose, and hormone levels
including FSH, LH, E2,P R L ,T S H ,t e s t o s t e r o n ea n d
DHEA-S are shown in Table 1. Consequently, the PCOS
patient group showed distinct difference compared with
the control group. The level of TSH, DHEA-S, and tes-
tosterone were slightly higher in the PCOS group.
Furthermore, 33 patients (15.2%) in the PCOS group
had hyperandrogenism and oligo- or amenorrhea, 18
patients (8.3%) in the PCOS group had hyperandrogen-
ism and polycystic ovaries, 141 patients (65%) in the
PCOS group had oligo- or amenorrhea and polycystic
ovaries, 22 patients (10.1%) in the PCOS group had
hyperandrogenism, oligo- or amenorrhea and polycystic
ovaries which are summarized in Table 2.
For the RFLP analysis for the -1031(T/C) polymorph-
ism of TNF-a gene, we recruited 217 patients and 144
control samples. In the present study, the frequency of
T/T, T/C, and C/C genotypes of -1031(T/C) polymorph-
ism in TNF-a gene was confirmed by sequence analysis
and it showed different proportion (p-value = 0.0003,
odd ratio (OR) = 2.53) between PCOS and control groups
(Figure 2, Table 3). According to the X
2 test, both groups
were in Hardy-Weinberg equilibrium (HWE). The fre-
quency of T/T genotype between PCOS and control
groups was 66.3% and 84.7%, respectively. The frequency
of T/C genotype between PCOS and control groups was
32.7% and 15.3%, respectively. And, the frequency of C/C
genotype between PCOS and control groups was 0.9%
and 0%, respectively. Our results demonstrated that there
was significant difference between PCOS and control
groups, indicating that there is strong association
between the -1031(T/C) polymorphism in the promoter
region of TNF-a gene and PCOS.
Discussion
TNF-a is a multifunctional proinflammation cytokine
and plays an important role in wide-range of various
diseases [19,20]. It exists not only in oocytes [21-24] and
granulosa cells [25-28], but also in follicular fluid of
human ovary [29-31]. It is considered to be related to
ovarian apoptosis, increased ovarian steroid secretion,
and anovulation [32,33]. Furthermore, it was reported
that serum level of TNF- a was shown to increase in
patients with PCOS. The TNF-a gene is known to cause
a decrease in insulin receptor tyrosine phosphorylation
and an increase in serine phosphorylation of insulin
receptor substrate, leading to inhibition of downstream
insulin signaling and glucose uptake [34].
TNF-a expression is regulated at both the transcrip-
tional and post-transcriptional levels. Moreover, TNF-a
gene transcription is regulated by the promoter region
which consists of an 1100 base pair of DNA [35,36].
Up to now, several studies of the -1031(T/C) poly-
morphism of TNF-a were reported including Behcet’s
disease [37], large joint arthropathy [38], and Crohn’s
disease [39]. Crohn’s disease and Behcet’s disease
patients showed the increased frequency of -1031C allele
compared with controls. In contrast, patients with
ulcerative collitis and hyperandrogenism showed lower
frequency of -1031C allele than that of controls [39,40].
In the present study, we investigated the influence of
-1031(T/C) polymorphism of TNF-a on PCOS by bio-
chemical, clinical, and molecular genetic approaches.
Our data showed that the -1031(T/C) polymorphism in
the promoter region of TNF-a gene is associated with
PCOS in a Korean population. Our study indicated that
the C allele may provide protection from PCOS, and
this promoter polymorphism has been associated with
Table 2 Comparison of clinical characteristics between PCOS patients (n = 217) and controls (n = 144)
Characteristics PCOS patients (n = 217) Controls (n = 144)
Hyperandrogenism and Oligo- or amenorrhea n = 33 (15.2%) n = 0 (0.0%)
Hyperandrogenism and Polycystic ovaries n = 18 (8.3%) n = 0 (0.0%)
Oligo- or amenorrhea and polycystic ovaries n = 141 (65%) n = 0 (0.0%)
Hyperandrogenism, Oligo- or amenorrhea and polycystic ovaries n = 22 (10.1%) n = 0 (0.0%)
Figure 1 The -1031(T/C) polymorphism of the TNF-a gene.
Shown is 2% agarose gel on the electrophoresis stained with
ethidium bromide following Bbs I digestion. The 251- and 13-bp
indicate the homozygosity of the T allele. However, 13-bp band was
not observed in 2% gel. 180-, 71-, and 13-bp indicated the
homozygosity of the C allele. And the T/C genotype indicates three
bands of 251-, 180-, and 71-bp.
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bowel diseases [41], rheumatoid arthritis [42], and breast
cancer [43]. Further studies are required to determine
the functional significance of the -1031C allele in PCOS.
This is the first study to demonstrate an association
between the -1031(T/C) polymorphism in the TNF-a
gene and PCOS. Genetic predisposition can be investi-
gated with association studies, and our results suggest
that it could be one of the etiological factors for PCOS
and that the -1031(T/C) polymorphism may play an
important role for the progression of PCOS.
Up to now, there is no transcriptional factor binding
to the -1031(T/C) polymorphism of TNF-a gene. It is
TT 
TC 
Figure 2 Sequence analysis for the -1031(T/C) polymorphism of TNF-a gene using forward primer.
Table 3 Allele frequencies of -1031(T/C) polymorphism of
TNF-a gene in PCOS group (n = 217) and control group
(n = 144)
PCOS patient group Control group
Genotypes, n (%)
TT 144 (66.5%) 122 (84.7%)
TC 71 (32.7%) 22 (15.3%)
CC 2 (0.9%) 0 (0.0%)
Alleles, n (%)
T 359 (82.7%) 266 (92.4%)
C 75 (17.3%) 22 (7.6%)
Total OR (95% CI) = 2.53 (1.53-4.17), p-value = 0.0003
Yun et al. Reproductive Biology and Endocrinology 2011, 9:131
http://www.rbej.com/content/9/1/131
Page 4 of 6very important to investigate the molecular mechanism
of the polymorphism for PCOS. Further studies are
required for the functional significance of the poly-
morphisms in TNF-a and may be suggested to be a
credible molecular and immunological marker. And
further association studies of PCOS with related genes
required for finding the pathogenesis of PCOS and
SNPs, which have association with PCOS important for
prediction and suggestion as a biomarker for diagnosis
of the disease.
In conclusion, this is the first report on the association
of -1031(T/C) polymorphism of TNF- a gene with
PCOS. These data might be very informative for the
advancement of future genetic treatment for PCOS
patients.
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